

Selpercatinib LIBRETTO-001 (Cohort 1)

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Selpercatinib LIBRETTO-001 (Cohort 1)

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Endocrine Tumours  
 Therapeutic Indication: Treatment of adults with RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib  
 Experimental Arm: Selpercatinib  
 Control Arm: Single arm



